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Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal interstitial lung disease (ILD) characterized by progressive fibrosis and loss of lung function \[[@CR1]\]. IPF is a rare disease and mainly affects older adults, with data from a US healthcare insurance claims database suggesting an incidence of 19.3 per 100,000 person-years in individuals aged 55--64 years \[[@CR2]\]. Historical data suggest a median time from diagnosis of IPF to death of only 2‒3 years \[[@CR1]\], but survival time following diagnosis is likely improving as patients are diagnosed earlier and are treated with drugs that slow disease progression \[[@CR3]--[@CR6]\].

Prompt diagnosis of IPF is important to ensure that patients receive appropriate care and support and have the opportunity to receive anti-fibrotic therapy and be evaluated for lung transplantation. Accurate diagnosis of IPF is critical, as other forms of ILD that have similar clinical presentations to IPF require different treatment strategies \[[@CR7]--[@CR11]\]. Imaging plays an essential role in the diagnosis of IPF \[[@CR1]\]. Once known causes of ILD have been excluded, a usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) is essentially diagnostic of IPF in the appropriate clinical setting \[[@CR1], [@CR12]\]. In addition, some non-UIP HRCT patterns strongly suggest an alternative diagnosis \[[@CR12]\]. Multidisciplinary discussion (MDD) between pulmonologists, radiologists and, where appropriate, pathologists and rheumatologists experienced in the diagnosis of ILD is key to establishing the diagnosis of IPF \[[@CR1], [@CR12], [@CR13]\]. However, the relay of information between radiologist and pulmonologist may be hampered by busy clinical schedules or misaligned expectations. In this review, we describe the central role of HRCT scans in the diagnosis of IPF and how clinical information provided by pulmonologists and other clinicians can aid radiologists in the interpretation of HRCT scans.

HRCT Scans in the Diagnosis of IPF {#Sec2}
==================================

Central to the diagnosis of IPF is the performance and interpretation of an HRCT scan \[[@CR1]\]. A surgical lung biopsy may be warranted if the HRCT pattern is inconclusive and the benefit of obtaining a more confident diagnosis outweighs the risks of conducting a biopsy in that patient \[[@CR12]\]. Current international guidelines for the diagnosis of IPF, published in 2011, state that the HRCT criteria for a definite UIP pattern characteristic of IPF are predominantly subpleural, basal reticular abnormalities in the presence of honeycombing, with or without traction bronchiectasis, and the absence of any of inconsistent features \[[@CR1]\]. Inconsistent features include: upper or mid-lung predominance, peribronchovascular predominance, extent of ground-glass abnormality greater than reticular abnormality, profuse micronodules (bilateral, predominantly upper lobes), discrete cysts (multiple, bilateral, away from areas of honeycombing), diffuse mosaic attenuation/air-trapping (bilateral, in three or more lobes), or consolidation in bronchopulmonary segment(s)/lobe(s). When performed correctly in the relevant patient population, UIP on HRCT has a high specificity for IPF \[[@CR14]--[@CR16]\]. However, it is important to note that our knowledge of radiological features that are diagnostic and characteristic of IPF comes from studies based on high-quality HRCT scans, not from more rudimentary radiographs. The classic studies that informed our knowledge of HRCT features in patients with IPF utilized protocols in which thin sections at 1--3 cm intervals were obtained using collimation sections of 1.0--3.0 mm and were reconstructed using a high-spatial-frequency algorithm \[[@CR17]--[@CR22]\], although current standard of care is to acquire images with volumetric CT and then to reconstruct at this slice reconstruction. In clinical practice, HRCT scans also need to be high-quality to ensure that key radiological features that are characteristic of IPF, or that would argue against a diagnosis of IPF, are apparent.

Current international guidelines for the diagnosis of IPF include recommendations for the optimal HRCT technique for evaluation of ILD \[[@CR1]\]. These include that non-contrast axial scans should be obtained in the supine position unless dependent density obscures detail, in which case prone scans can be used (with the option of coronal and sagittal reconstructions if volumetric images are obtained). In many expert centers, both supine and prone images are acquired, and this is becoming (and some argue, has become) standard of care. The field of view should include only the lungs to maximize in-plane spatial resolution. Scans should be obtained during full inspiration without respiratory motion. An expiratory scan is helpful to exclude lobular air-trapping suggestive of hypersensitivity pneumonitis or connective tissue disease and is a mandatory part of the HRCT protocol for evaluation of ILD. Thin sections (≤ 2 cm intervals) can be contiguous or non-contiguous and images should be reconstructed using a high-spatial-frequency reconstruction algorithm. Though not essential, coronal and sagittal reformations can be helpful in determining the distribution of disease as well as identifying subtle honeycombing.

The Importance of Multidisciplinary Discussion in Differential Diagnosis of ILD {#Sec3}
===============================================================================

MDD involving a radiologist, a pulmonologist and, when necessary, a pathologist, with experience in the differential diagnosis of ILD is the gold standard in the diagnosis of IPF \[[@CR1], [@CR12], [@CR13]\] and has been shown to improve the confidence of the diagnosis \[[@CR23], [@CR24]\]. In a classic study in which clinicians, radiologists, and pathologists were provided with clinical, HRCT, and histopathological data from 58 cases of suspected idiopathic interstitial pneumonia in a stepwise fashion, interdisciplinary agreement improved as more data were provided and the case was discussed \[[@CR23]\]. In a recent study in which data from 70 patients with diffuse parenchymal lung disease were evaluated by seven multidisciplinary teams, MDD was associated with the assignment of a diagnosis of IPF with high confidence more frequently than when diagnoses were made by clinicians or radiologists alone; further, supporting the validity of the diagnoses made following MDD, there was a greater separation in the mortality rates of patients with an IPF versus non-IPF diagnosis made by the multidisciplinary teams than by clinicians or radiologists alone \[[@CR24]\].

A white paper recently published by the Fleischner Society \[[@CR12]\] proposed that not all patients with suspected IPF require MDD. Rather, MDD is necessary when the clinical context and/or HRCT pattern are inconclusive (to determine additional clinical evaluations), after biopsy (to integrate clinical, imaging, and histological findings), to consider a working diagnosis in patients who do not fulfill all the diagnostic criteria for any specific type of ILD (i.e., who are not adequately covered by the existing evidence base), and to revisit cases where the disease course is discordant with the established diagnosis. When a working diagnosis of IPF is made, the patient should be closely monitored, with repeat of clinical, radiological, and laboratory assessments as appropriate, so that their diagnosis can be reviewed at regular intervals (ideally based on further rounds of MDD).

While it can be challenging to convene a multidisciplinary team face-to-face, MDD can be conducted virtually or by telephone to enable each specialty group to contribute. To make the MDD most effective, comprehensive clinical and HRCT data should be made available in advance of the MDD so that all parties can consider the case in advance. A common understanding among all parties of the terms used to describe HRCT features observed in ILD \[[@CR25]\] can also help improve the effectiveness of MDD. When IPF is considered in the differential diagnosis, the radiologist should advise whether a UIP pattern is present and, if so, their level of confidence, based on evaluation of image quality and the distribution and extent of specific disease features defined based on standard terminology. The identification of a UIP pattern can be more challenging in patients (usually ex-smokers) who have both lung fibrosis and emphysema. In such cases, radiologists should describe the extent and severity of emphysema as well as UIP, as this may influence patient management, evaluation and prognosis. It is important that the outcome of the MDD is adequately documented, including the first choice diagnosis (which may be "unclassifiable disease"), realistic differential diagnoses, likely reversibility of the patient's disease, and recommendations on additional diagnostic tests \[[@CR12]\].

Clinical Information to Aid the Interpretation of HRCT Scans {#Sec4}
============================================================

Clinical information is key to the interpretation of HRCT scans, as the likelihood that specific radiologic features reflect IPF is not absolute, but dependent on the clinical context. Indeed, making a diagnosis of IPF specifically requires the exclusion of known causes of ILD, including autoimmune diseases, exposure to potential inducers of chronic hypersensitivity pneumonitis, occupational exposures, and the use of certain drugs \[[@CR26]\]. To assist the radiologist in contributing to the MDD, it is important that they have access to relevant information on the patient's clinical history, exposures and the results of other tests that have been performed (Table [1](#Tab1){ref-type="table"}). While the radiologist does not need to know every detail, if the pulmonologist or other clinician involved in the care of the patient has suspicions as to the cause of the patient's lung disease, it is valuable for the radiologist to be made aware of them prior to the MDD. For example, laboratory tests may reveal the presence of autoantibodies suggestive of an autoimmune disease (e.g., antinuclear antibodies, anti-cyclic citrullinated peptide, rheumatoid factor) \[[@CR1], [@CR11]\], while serologic testing for IgG antibodies against potential antigens can provide supportive evidence for hypersensitivity pneumonitis \[[@CR9], [@CR27]\]. It is important that clinicians perform a thorough patient interview to ascertain exposures to potential inducers of hypersensitivity pneumonitis such as avian antigens or microbial agents, as chronic hypersensitivity pneumonitis may have a similar clinical and radiological presentation to IPF \[[@CR9], [@CR27], [@CR28]\]. Environmental exposures that increase the risk of ILD include asbestos, metal or wood dust, and farming \[[@CR1]\]. A clinical judgment may need to be made as to whether exposure to such factors is the cause of the ILD, or simply a background exposure in a patient who has developed an idiopathic interstitial pneumonia. Information on any prescribed medications should also be provided to the radiologist. Therapies that have been associated with a UIP-like pattern of pulmonary toxicity include chemotherapeutic agents, antiarrhythmic drugs, and immunosuppressive agents \[[@CR29]\].

Table 1Factors to be considered in making a differential diagnosis in patients with suspected ILDAgeGenderSigns and symptoms Inspiratory "Velcro" crackles or "squeaks" on chest auscultation Involvement of other organs that may indicate autoimmune diseasePulmonary function tests (PFTs) FVC, DLco, FEV~1~Laboratory tests that may indicate autoimmune disease or hypersensitivity pneumonitisOccupational/environmental exposures Smoking Potential inducers of hypersensitivity pneumonitis e.g., birds Exposures to compounds known to cause ILD e.g., asbestos, metal dustResponse/non-response to therapies used to treat lung diseaseUse of medications known to cause ILDFamily historyFeatures on HRCTFeatures on surgical lung biopsy, if available

The typical presentation of IPF is a male ex-smoker over the age of 50 years who presents with chronic exertional dyspnea and cough and has "Velcro"-like bibasilar inspiratory crackles on auscultation of the chest \[[@CR1], [@CR30], [@CR31]\]. In patients with IPF, pulmonary function tests (PFTs) typically demonstrate a restrictive pattern (i.e., reduced total lung capacity, FVC, and diffusing capacity for carbon monoxide \[DL~CO~\] with a normal ratio of forced expiratory volume in one second \[FEV~1~\] to FVC) \[[@CR32], [@CR33]\]. However, it should be noted that some patients with IPF have an almost normal FVC% predicted early in the course of their disease \[[@CR34]\] and that patients who began with an FVC of over 100% predicted may have lost a substantial amount of lung function and still have an FVC% predicted that appears normal. Further, it should be remembered that concomitant emphysema, which is present in about a third of patients with IPF, increases FVC \[[@CR35]\].

A family history of pulmonary fibrosis should prompt consideration of familial interstitial pneumonia, although this is very rare \[[@CR1]\]. Several mutations have been associated with an increased risk of IPF including those in genes for surfactant proteins (SFTPA2, SFTPC), telomerase reverse transcriptase (TERT), the RNA component of telomerase (TERC), and TOLLIP and MUC5B, which play important roles in lung host defense \[[@CR36], [@CR37]\]. Interestingly, there is emerging evidence that different polymorphisms may be associated with different patterns of fibrosis on HRCT \[[@CR38]\].

Patient Case Studies {#Sec5}
====================

Patient Case 1 {#Sec6}
--------------

A 72-year-old man presented with chronic cough, dyspnea on exertion and basilar crackles on chest auscultation. Comorbidities included coronary artery disease, hypertension, and type 2 diabetes. He was a current smoker. PFTs showed restrictive physiology (DL~CO~ of 50% predicted and FVC of 65% predicted). An HRCT scan showed definite features of UIP (Fig. [1](#Fig1){ref-type="fig"}). A consensus diagnosis of IPF was made based on the characteristic presentation in combination with definite features of UIP on HRCT and exclusion of other known causes of UIP. A lung biopsy was regarded as unnecessary and was not performed.

Fig. 1Axial (**a**) and coronal (**b**) HRCT images show peripheral and basilar predominant pulmonary fibrosis characterized by reticulation, traction bronchiectasis, traction bronchiolectasis and subpleural honeycombing consistent with UIP

Patient Case 2 {#Sec7}
--------------

A 48-year-old woman presented with chronic dyspnea, mild cough, and mild basilar crackles and "squeaks" on chest auscultation. She was a former smoker (10 pack-year history) and had a significant exposure history for parakeets, dogs, and guinea pigs. She also had a history of asthma and arthritis. PFTs showed a DL~CO~ of 65% predicted and FVC of 62% predicted. An HRCT scan showed possible UIP (Fig. [2](#Fig2){ref-type="fig"}) but the patient's age (\< 50 years) and clinical history suggested an alternative diagnosis than IPF. A consensus diagnosis of hypersensitivity pneumonitis was made given the patient's exposures and the fact that hypersensitivity pneumonitis can present with imaging features similar to UIP.

Fig. 2Axial (**a**--**d**) HRCT images show peripheral and basilar predominant pulmonary fibrosis characterized by reticulation, traction bronchiectasis, and traction bronchiolectasis but no honeycombing, consistent with a possible UIP pattern

Patient Case 3 {#Sec8}
--------------

A 67-year-old woman presented with chronic cough, fatigue, and mild basilar crackles on chest auscultation. She was a current smoker with a 20 pack-year history. Exposure history was significant for cats. She had a history of gastroesophageal reflux disease, hypertension, and migraines and comorbidities including back pain, and intermittent constipation and diarrhea. PFTs revealed a DL~CO~ of 60% predicted and FVC of 70% predicted. Laboratory findings were mildly positive for antinuclear antibody and C-reactive protein. An HRCT scan was inconsistent with UIP and most suggestive of a non-specific interstitial pneumonia pattern (Fig. [3](#Fig3){ref-type="fig"}). However, a working diagnosis of IPF was made given that the patient's clinical history and physical examination were suggestive of IPF and no alternative cause for the patient's interstitial pneumonia was identified. After 2 years of follow-up, the patient had joint pain and was positive for anti-cyclic citrullinated peptide and rheumatoid factor, and was diagnosed with rheumatoid arthritis.

Fig. 3Axial (**a**) and coronal (**b**) HRCT images show basilar predominant ground-glass opacity, mild reticulation, mild traction bronchiectasis, and areas of relative subpleural sparing in the lower lobes. These findings are highly suggestive of non-specific interstitial pneumonia (NSIP)

Conclusions {#Sec9}
===========

Central to the diagnosis of ILD is an HRCT scan performed and interpreted by an expert radiologist. However, the likelihood that specific radiologic features reflect IPF is dependent on the clinical context. Although both radiologists and pulmonologists can identify findings that suggest an ILD, neither can make a differential diagnosis without input from the other. In cases where the diagnosis is not clear based on the patient's radiological and clinical features, MDD is required to agree on the most appropriate diagnosis. For some patients, a working diagnosis is appropriate, but this should be reviewed at regular intervals as new information pertinent to the patient's diagnosis may become available over time. Diagnostic guidelines for IPF will be revised in future to reflect our growing knowledge of the clinical course of patients with specific clinical and radiological features, as well as new information on molecular signatures that predict UIP.
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